Literature DB >> 15629882

CBLB variants in type 1 diabetes and their genetic interaction with CTLA4.

Regine Bergholdt1, Camilla Taxvig, Stefanie Eising, Jørn Nerup, Flemming Pociot.   

Abstract

Type 1 diabetes (T1D) is a multifactorial disease with genetic and environmental components involved. Recent studies of an animal model of T1D, the Komeda diabetes-prone rat, have demonstrated that the Casitas-B-lineage lymphoma b (cblb) gene is a major susceptibility gene in the development of diabetes and other autoimmune features of this rat. As a result of the inhibitory role of Cbl-b in T cell costimulation, dysregulation of Cbl-b may also contribute to autoimmune diseases in man. Different isoforms of Cbl-b exist; we evaluated expression levels of two known transcript variants. Constitutive expression of both isoforms was demonstrated, as well as an increased expression, after cytokine exposure, of an isoform lacking exon 16, suggesting a possible role of this variant in the pathogenesis of autoimmunity. We screened coding regions of the human CBLB gene for mutations in a panel of individuals affected with several autoimmune diseases. Eight single nucleotide polymorphisms (SNPs) were detected. One SNP in exon 12 of the CBLB gene was significantly demonstrated to be associated to T1D in a large Danish T1D family material of 480 families. Evidence for common genetic factors underlying several autoimmune diseases has come from studies of cytotoxic T lymphocyte antigen 4 (CTLA4), which encodes another negatively regulatory molecule in the immune system. Gene-gene interactions probably play substantial roles in T1D susceptibility. We performed stratification of CBLB exon 12 SNP data, according to an established CTLA4 marker, CT60, and evidence for a genetic interaction between the CTLA4 and CBLB genes, involved in the same biological pathway of T cell receptor signaling, was observed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629882     DOI: 10.1189/jlb.0904524

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  23 in total

1.  Gene-gene interaction between tuberculosis candidate genes in a South African population.

Authors:  Erika de Wit; Lize van der Merwe; Paul D van Helden; Eileen G Hoal
Journal:  Mamm Genome       Date:  2010-08-27       Impact factor: 2.957

2.  Myostatin induces insulin resistance via Casitas B-lineage lymphoma b (Cblb)-mediated degradation of insulin receptor substrate 1 (IRS1) protein in response to high calorie diet intake.

Authors:  Sabeera Bonala; Sudarsanareddy Lokireddy; Craig McFarlane; Sreekanth Patnam; Mridula Sharma; Ravi Kambadur
Journal:  J Biol Chem       Date:  2014-01-22       Impact factor: 5.157

Review 3.  Signaling mechanisms regulating B-lymphocyte activation and tolerance.

Authors:  Elias Hobeika; Peter J Nielsen; David Medgyesi
Journal:  J Mol Med (Berl)       Date:  2015-01-29       Impact factor: 4.599

Review 4.  c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.

Authors:  Christine B F Thien; Wallace Y Langdon
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

5.  Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.

Authors:  Cielito C Reyes-Gibby; Sanjay Shete; Trude Rakvåg; Samrat V Bhat; Frank Skorpen; Eduardo Bruera; Stein Kaasa; Pål Klepstad
Journal:  Pain       Date:  2006-12-06       Impact factor: 6.961

6.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

7.  Posttranslational Protein Modifications in Type 1 Diabetes - Genetic Studies with PCMT1, the Repair Enzyme Protein Isoaspartate Methyltransferase (PIMT) Encoding Gene.

Authors:  Ana M Wägner; Paul Cloos; Regine Bergholdt; Stefanie Eising; Caroline Brorsson; Martin Stalhut; Stephan Christgau; Jørn Nerup; Flemming Pociot
Journal:  Rev Diabet Stud       Date:  2009-02-10

Review 8.  E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.

Authors:  Qingjun Liu; Hong Zhou; Wallace Y Langdon; Jian Zhang
Journal:  Cell Cycle       Date:  2014-05-14       Impact factor: 4.534

9.  Inhibition of CBLB protects from lethal Candida albicans sepsis.

Authors:  Gerald Wirnsberger; Florian Zwolanek; Tomoko Asaoka; Ivona Kozieradzki; Luigi Tortola; Reiner A Wimmer; Anoop Kavirayani; Friedrich Fresser; Gottfried Baier; Wallace Y Langdon; Fumiyo Ikeda; Karl Kuchler; Josef M Penninger
Journal:  Nat Med       Date:  2016-07-18       Impact factor: 53.440

10.  Signature RNAS and related regulatory roles in type 1 diabetes mellitus based on competing endogenous RNA regulatory network analysis.

Authors:  Qinghong Shi; Hanxin Yao
Journal:  BMC Med Genomics       Date:  2021-05-18       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.